Physician profile
Daniel A Osimani
NPI 1255397816
$7,944.90
in general payments reported to CMS, 2019-2025
47 companies · $1,105 in 2025
The $1,105 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,021 · 2020: $845 · 2021: $1,275 · 2022: $1,350 · 2023: $1,224 · 2024: $1,124 · 2025: $1,105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,453.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,452.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $919.41 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $549.66 | 2019-2025 | Xarelto, Spravato |
| Amgen INC. | $503.96 | 2019-2024 | Repatha |
| Novartis Pharmaceuticals Corporation | $467.43 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $407.58 | 2021-2025 | Verquvo, Belsomra, Steglatro |
| Boston Scientific Corporation | $383.32 | 2019-2024 | Lux-Dx Insertable Cardiac Monitor, Watchman Flx, Emblem Mri S-Icd |
| Novo Nordisk INC | $378.23 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $347.25 | 2019-2025 | |
| Celonova Biosciences, INC. | $325.92 | 2019-2020 | |
| Cvrx, INC. | $318.40 | 2020-2025 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $307.45 | 2020-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals Lp | $298.32 | 2019-2025 | Farxiga, Lokelma, Brilinta |
| Esperion Therapeutics, INC. | $253.64 | 2020-2024 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $231.74 | 2019-2025 | Jardiance |
| Abiomed | $230.68 | 2022-2024 | Impella |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $179.09 | 2020-2025 | Opsumit |
| Abbott Laboratories | $163.59 | 2021-2023 | Aveir |
| Philips North America LLC | $134.56 | 2020-2025 | Ecc Solutions |
| Recor Medical INC | $121.83 | 2024 | Paradise Renal Denervation System |
| Edwards Lifesciences Corporation | $117.14 | 2025 | Sapien 3 Ultra Resilia |
| Lilly USA, LLC | $106.36 | 2024-2025 | Zepbound, Mounjaro |
| Lexicon Pharmaceuticals, INC. | $98.80 | 2023-2024 | Inpefa |
| Baxter Healthcare | $90.00 | 2023-2024 | Hillrom - Carnation Ambulatory Monitor |
| Medtronic Vascular, INC. | $83.64 | 2019 | |
| Dexcom, INC. | $82.96 | 2024-2025 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $76.26 | 2024-2025 | Caplyta |
| Lundbeck LLC | $76.04 | 2019 | |
| Vital Connect, INC | $72.92 | 2023 | Vitalpatch Rtm |
| Chiesi USA, INC. | $71.20 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $70.99 | 2022-2023 | Quviviq |
| United Therapeutics Corporation | $66.38 | 2024 | Tyvaso |
| Mannkind Corporation | $55.28 | 2022 | |
| Irhythm Technologies, INC. | $41.41 | 2024 | Zio Xt Patch, Zio Monitor |
| Xeris Pharmaceuticals, INC. | $41.33 | 2021 | |
| Kiniksa Pharmaceuticals, Ltd. | $32.81 | 2022-2023 | Arcalyst |
| Amarin Pharma, INC. | $29.26 | 2021-2022 | |
| Braemar Manufacturing, LLC | $26.32 | 2019 | |
| Siemens Medical Solutions USA, INC. | $23.21 | 2022 | |
| Biogen, INC. | $21.83 | 2023 | Skyclarys |
| Nestle Healthcare Nutrition INC. | $21.13 | 2023 | |
| Cardiovascular Systems INC. | $19.04 | 2023 | Diamondback Coronary |
| Bayer Healthcare Pharmaceuticals INC. | $18.03 | 2022 | |
| Itamar Medical INC | $17.43 | 2023 | Watchpatone |
| Abbvie INC. | $17.36 | 2025 | |
| Glaxosmithkline, LLC. | $16.69 | 2025 | Arexvy, Shingrix |
| Exact Sciences Corporation | $15.37 | 2025 | Cologuard Collection Kit |
| Regeneron Healthcare Solutions, INC. | $13.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Osimani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.